Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant eribulin after anthracycline and taxane in triple negative breast cancer
2012-004956-12Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in triple-negative breast cancer (TNBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathological complete response in breast and axilla. Started Jan 2013; status: terminated.
02
Drugs
eribulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2012-004956-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004956-12.